We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
European regulators yesterday told the European Union ombudsman that they adhered to the law when allowing manufacturer AbbVie to redact information from its clinical study reports, marking the latest twist in the debate over European trial data transparency. Read More
A key Senate health panel will consider a bipartisan bill to hasten the development of Ebola drugs by including the disease under a lucrative voucher program. Read More
The European Medicines Agency has released an online tool designed to help manufacturers report and edit information on their marketed products, as required under the 2010 pharmacovigilance law. Read More
The Scottish Medicines Consortium has approved five new medicines for reimbursement in Scotland, including treatments for cancer, hepatitis C and diabetes. Read More
The European Medicines Agency has lent its support to an initiative to qualify biomarkers that can provide an early warning on an investigational compound’s risks of causing drug-induced kidney injuries, an endorsement that researchers say is necessary to move to the next phase of development. Read More
The FDA has cited Cadila Pharmaceuticals for poor data integrity practices and sloppy investigations into foul smelling batches of active pharmaceutical ingredients (APIs), violations that the agency threatened could result in an import alert. Read More
Drugmakers can now access all regulatory advice on regenerative medicines in the UK through a single web portal, thanks to a government initiative launched Oct. 13. Read More
The Australian government plans fast-track approvals and joint drug reviews with other countries, following an independent review aimed at making the drug approval process less redundant and easier to understand. Read More
Australia’s medicines authority is urging tougher warnings on the cardiovascular risks of over-the-counter nonsteroidal anti-inflammatory drugs, as well as new initiatives to inform patients about the risks associated with both OTC and prescription versions of the painkillers. Read More
Access to a forthcoming clinical trials portal and database would be limited to authorized users and “super users,” under draft specifications released by the European Medicines Agency.
Read More